1Mafee M F. MRI and CT in the evaluation of acquired and congenital cholesteatomas of the temporal bone. J Otolaryngol, 1993,22 :239-248.
2Fageeh N A, Schloss M D, Elahi M M, et al. Surgical treatment of cholesteatoma in children. J Otolaryngol,1999,28:309-312.
3Mutlu C, Khashaba A, Saleh E, et al. Surgical treatment of cholesteatoma in children. Otolaryngol Head Neck Surg,1995,113:56-60.
4Karmarkar S, Bhatia S, Saleh E, et al. Cholestcatoma surgery: the individualized technique. Ann Otol Rhinol Laryngol, 1995,104: 591 - 595.
5Albino A P, Reed J A, Bogdany J K. Expression of p53protein in human middle ear cholesteatomas. Pathogenetic implications. Am J Otol, 1998,19:7930- 7936.
6Choufani G, Mahillon V, Decaestecker C, et al. Determination of the levels of expression of sarcolectin and calcycln and of the percentages of apoptotic but not proliferating cells to enable distinction between recurrent and nonrecurrent cholesteatomas. Laryngoscope, 1999,109:1825-1831.
7Haake A R,Cooklis M. Incomplete differentiation of fetal keratinocytes in the skin equivalent leads to the default pathway of apoptosis. Exp Cell Res, 1997, 231:83-95.
8Lu Y,Lotan D,Lotan R. Differential regulation of constitutive and retinoic acid-induced galectin-1 gene transcription in murine embryonal carcinoma and myoblastic cells. Biochim Biophys Acta, 2000,1491:13- 19.
